secwatch.observer — SEC 8-K summary
======================================

Issuer:     Merck & Co., Inc. (MRK)
CIK:        0000310158
Form:       8-K
Filed at:   2025-07-29T23:59:59+00:00
Accession:  0001104659-25-071380
Event type: earnings
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud

Merck reports Q2 2025 sales of $15.8B, down 2%, and announces $3B restructuring program
--------------------------------------------------------------------------------

- Total worldwide sales $15.8 billion, down 2% nominally and ex-forex vs Q2 2024; KEYTRUDA sales $8.0 billion, up 9%.
- GAAP EPS $1.76, Non-GAAP EPS $2.13; includes $0.07 per share charge for Hengrui Pharma license agreement.
- GARDASIL/GARDASIL 9 sales $1.1 billion, decline of 55% primarily due to lower demand in China.
- Approved 2025 Restructuring Program with cumulative pretax cost ~$3.0 billion, expected annual savings ~$1.7 billion by end of 2027.
- Announced agreement to acquire Verona Pharma for ~$10 billion, adding COPD treatment Ohtuvayre; expected close Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/310158/000110465925071380/0001104659-25-071380-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/310158/000110465925071380/tm2521736d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-071380

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer